Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18:v1–75.
2. Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–8.
3. Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090.
4. Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, et al. The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci. 2012;19:1530–4.
5. Roger Stupp MDWP, Michael Weller MDBF, Karl Belanger MDAA, Ulrich Bogdahn MDJC, Samuel K, Ludwin MDTG, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;9:196–7.